March 22, 2023
Maze Therapeutics
Maze Therapeutics Announces New Clinical Data Supporting MZE001 as a Potential Treatment for Pompe Disease
March 22, 2023
Flare Therapeutics
Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing
March 21, 2023
Decibel Therapeutics
Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors
March 14, 2023
Decibel Therapeutics
Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
March 13, 2023
Pliant Therapeutics
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis